Text and Data Mining valid from 2018-07-03
Received: 29 December 2017
Accepted: 20 June 2018
First Online: 3 July 2018
Ethics approval and consent to participate
: The Ethics committee from Hospices Civils de 390 Lyon has approved this retrospective study. Eligible patients were selected from two 391 prospective studies: “MELBASE” and “PAIR”. Melbase is a French multicenter prospective 392 database following patients starting first-line treatment for stage IV melanoma (NCT 393 02828202). PAIR (Programme d’Actions Intégrées de Recherche) is a single center cohort of 394 patients treated with nivolumab as second line of therapy (NCT 02626065). All patients gave 395 their written informed consent to participate in these databases.
: Not applicable
: The authors declare that they have no competing interests. However, several authors have received funding for work not related to this manuscript.Dr Mona Amini-Adle is co-investigator in several clinical trials conducted by Roche Genetech, BMS, Merck Serono, Novartris. She received travel costs covered by BMS, AMGEN.Dr Nagham Khanafer reports a PhD grant from Sanofi Pasteur, non-financial support (travel expenses) from Alere, Astellas and Sanofi Pasteur and personal fees from Astellas.Pr Stéphane Dalle is either principal investigator or co-investigator in several clinical trials conducted by Roche Genetech, BMS, Merck Serono, Novartris. He received a research grant (not related with the present work) and travel costs covered by Roche Genetech, BMS.All authors declare that they have sufficiently participated in the submitted work to deserve authorship, all have had access to clinical material and have revised the manuscript before submission.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.